1. Scrip
  2. >>Business
  3. >>Financing

InDex Gets Cash Boost For Phase III Ulcerative Colitis Drug

Swedish Firm's Cobitolimod Could Be A Blockbuster

 
• By Kevin Grogan

The Stockholm-based company is in a position to start the Phase III program for its ulcerative colitis candidate after raising over $64m in a rights issue.

Swedish flags
Index flying the flag for Swedish biotechs • Source: Archive

It has been a long road but Sweden's InDex Pharmaceuticals Holding AB is moving its investigational ulcerative colitis drug cobitolimod into Phase III armed with a sizeable cash pot following a successful financing.

The Stockholm-based group has signed off a rights issue that has raised SEK533m ($64.2m) consisting of around 444 million new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By Manas Mishra

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By Vibha Ravi

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis

Verona’s COPD Launch Success Sealed Merck Buyout Interest

 
• By Andrew McConaghie

SEC filings reveal that Merck was the sole bidder for Verona and its COPD drug Ohtuvayre, with the final $10bn deal wrapped up within a month.